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TECHNICAL REPORT
ANTIRETROVIRAL ACTIVITY OF PROTEASE INHIBITORS AGAINST Toxoplasma gondii 
Lianet MONZOTE(1), Marta RODRÍGUEZ(1), Yenisey ALFONSO(1) & Raymundo COX(1)
SUMMARY
The introduction of highly active antiretroviral therapy (HAART) has caused a marked reduction in the occurrence and severity 
of parasitic infections, including the toxoplasmic encephalitis (TE). These changes have been attributed to the restoration of cell-
mediated immunity. This study was developed to examine the activity of six antiretroviral protease inhibitors (API) on Toxoplasma 
gondii tachyzoites. The six API showed anti-Toxoplasma activity, with IC50 value between 1.4 and 6.6 µg/mL. Further studies at the 
molecular level should be performed to clarify if the use of API could be beneficial or not for AIDS patients with TE.
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Toxoplasma gondii is a widely distributed apicomplexan parasite of 
great medical importance. Most primary infections are asymptomatic, 
and may affect up to one-third of the human population worldwide7. 
In immunocompromised patients, especially those with acquired 
immunodeficiency syndrome (AIDS), reactivation of latent infection 
causes necrotic lesions producing life threatening encephalitis9. The 
introduction of highly active antiretroviral therapy (HAART) has 
caused a marked reduction in the occurrence and clinical course of 
different parasitic infections, including toxoplasmic encephalitis 
(TE). Although these changes have been attributed to the restoration 
of cell-mediated immunity induced by either non-nucleoside reverse 
transcriptase inhibitors or protease inhibitors, in combination with at 
least two nucleoside reverse transcriptase inhibitors included in HAART, 
there are evidences that antiretroviral protease inhibitors (APIs) have a 
direct inhibitory effect on the proteases of some parasites4. Previously, 
experimental studies demonstrated the antiparasitic activity of APIs 
against Plasmodium falciparum10 and Leishmania spp13. Against T. 
gondii, the in vitro inhibition has been observed for two protease 
inhibitors (indinavir and nelfinavir)6. The aim of this study was to 
investigate the in vitro effects against T. gondii of six available APIs, 
which are used in the treatment of Cuban patients with AIDS. 
Tachyzoites of the virulent T. gondii RH strain maintained through 
serial intraperitoneal passages in Swiss mice were used. Tachyzoites 
were harvested from mouse peritoneal fluids 72 h post-infection and 
purified by centrifugation and needle extraction in the moment of use.
Female Swiss Webster mice, with a body weight of approximately 22 
to 26 g, were obtained from The National Centre of Laboratory Animals 
Production (CENPALAB), Cuba. The animals were kept according to 
“Guidelines on the Care and Use of Laboratory Animals”. 
Atazanavir (Bristol-Myers Squibb, USA), fosamprenavir 
(GlaxoSmithKline, United Kingdom), indinavir (Novatec, Havana 
City, Cuba), nelfinavir (CIPLA, India), ritonavir (CIPLA, India) and 
saquinavir (Hoffmann-La Roche SA Basilea, Switzerland) were dissolved 
in dimethylsulfoxide (DMSO) at final concentration of 10 mg/mL. 
Sulfadiazine and pyrimethamine (Ipca Laboratories Ltd, India) was used 
as reference drug dissolved in DMSO. The products were stored at 4 ºC.
Biological evaluation: Resident macrophages were collected from the 
peritoneal cavities of normal Swiss Webster mice in ice-cold RPMI 1640 
medium (SIGMA, St. Louis, Mo, USA) supplemented with antibiotics, 
and seeded at 3 x 105 cell/well in a 24 well plate and incubated for two 
hours at 37 ºC in 5% CO2. Non-adherent cells were removed by washing 
with PBS, and then, T. gondii tachyzoites were added at a 1:3 parasite/
macrophage ratio, and the cultures were incubated for one hour. Free 
parasites were removed by washing and the drugs were added at final 
concentrations between 1.25 to 10 µg/mL. The cultures were incubated 
for 48 h in same conditions. The cells and parasites were then fixed 
in absolute methanol, stained with Giemsa, and examined under light 
microscopy. The percentage of infected macrophage was determined 
by the counting of 1000 cells. The IC50 value was determined from the 
lineal equation obtained from concentration-response curves8. Three 
replicates were carried out and the results are presented as average ± 
standard deviation.
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Cytotoxicity assay: Resident macrophages were collected and seeded 
as previously described in plates of 96 wells. Dilutions of the APIs were 
added and the cytotoxicity was determined after three days of incubation 
using a colorimetric assay with 15 mL of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) (SIGMA, St. Louis, MO, USA) 
and an additional incubation for four hours. The formazan crystals were 
dissolved by the addition of 100 mL of DMSO and the optical density was 
determined using an EMS Reader MF Version 2.4-0, at a test wavelength 
of 560 nm and a reference wavelength of 630 nm15. The 50% cytotoxic 
concentration (CC50) was obtained from dose-response curves fit to data 
by means of the equation for the sigmoidal E
max
 model2. Three replicates 
were carried out and the results are presented as average ± standard 
deviation. Selectivity indices (SI) were then calculated by dividing the 
CC50 for peritoneal macrophage of mice by the IC50 for T. gondii3.
Statistical analysis: The three values of IC50 obtained from each 
experiment were used and compared by Mann-Whitney test (Statistical 
for Windows Program, Release 4.5, StatSoft, Inc. 1993). Statistical 
differences were when p < 0.05.
The APIs were evaluated against intracellular tachyzoites resident in 
peritoneal macrophage from OF-1 mice. All tested APIs demonstrated 
anti-Toxoplasma activity at micromolar concentrations after 48 hours 
(Table I). The best activity was shown by atazanavir, which had a 
statistically different IC50 value (p < 0.05) compared with the other APIs. 
The compounds were toxic to mammalian host, with selectivity index 
from 6 to 15 and IC50 values from 15.9 to 76.8 µg/mL. Sulfadiazine 
and pyrimethamine were active in a similar concentrations reported3,5. 
Nevertheless, both compounds showed higher cytotoxicity compared 
with APIs, with selectivity index of 4 and 1, respectively. 
Several studies concerning Toxoplasma/HIV co-infections have been 
published; particularly focused on diagnosis, pathogenesis and treatment. 
The treatment of these patients with APIs has been considered as one of 
the more promising studies. Currently, APIs have been also reported as 
potential drugs for the treatment of intracellular protozoa. All compounds 
studied have been used to treat HIV patients due to their potent in vitro 
antiviral activity. Specifically for T. gondii, all evaluated APIs exhibited 
in vitro activity and were selectivity better than other clinically used drugs 
such as sulfadiazine and pyrimethamine. Calculated IC50 were similar to 
those previously reported by DEROUIN & SANTILLANA-HAYAT which 
reported that nelfinavir and ritonavir showed an IC50 of 4.0 and 5.4 µg/
mL, respectively6. The activity showed by PI, together with their cellular 
permeability properties could justify the further exploration of APIs as 
anti-Toxoplasma drugs in TE and ocular infections. In addition, available 
APIs can gain roles as treatment for toxoplasmic complicated infections 
due to availability of the drug and potential activity on resistant strains6.
The mode of action of APIs on parasites, including T. gondii, still 
needs to be clarified. Nevertheless, in protozoan parasites the aspartyl 
protease enzymes seem to play important roles in the life cycle and 
display diverse functions, including the invasion of host cells and tissues, 
the degradation of mediators of the immune response and the hydrolysis 
of host proteins for nutritional purposes11,12. For T. gondii, seven genes 
coding for putative aspartic proteases have been identified with known 
human and apicomplexan proteases13. In this sense, SANTOS et al. 
demonstrated that nelfinavir powerfully inhibited the hydrolysis of HIV 
peptidase substrate by L. amazonensis extract12; while ANDREWS et 
al. reported that in vitro enzyme assays with plasmepsins II and IV 
from P. falciparum are both inhibited by saquinavir and ritonavir1. 
Further experiments with toxoplasma enzyme are required to back up 
this hypothesis.
In conclusion, our results demonstrated for the first time the potential 
activity of APIs (atazanavir fosamprenavir, indinavir and saquinavir) 
against T. gondii, which have not been reported previously. In this 
sense, in vitro data suggest the possibility that HIV patients receiving 
PI therapy might also benefit from an effect against Toxoplasma due to 
inhibition of parasite growth, and consequently limiting the development 
of the TE disease. Further studies about the method of the action of APIs 
using T. gondii enzymes, as well as the interaction with the co-infection 
HIV-parasite can help to clarify the influence of API in the development 
of TE in AIDS patients. In addition, new strategies can be useful in 
designing new PI with specific activity on protozoa parasites, as well as 
the exploration of their potential in patients infected only with T. gondii.
RESUMEN
Terapia antiretroviral de inibidores da protease contra 
Toxoplasma gondii
La introducción de la terapia antirretroviral de alta efectividad ha 
causada una marcada reducción en la ocurrencia y curso clínico de 
las infecciones parasitarias, incluyendo la toxoplasmosis encefálica 
(TE). Estos cambios han sido atribuidos a la restauración celular. Este 
estudio fue desarrollado para examinar la actividad de seis inhibidores 
de proteasas antirretrovirales (IPA) sobre taquizoitos de Toxoplasma 
gondii. Los seis IPA mostraron actividad anti-Toxoplasma, con valores 
de CI50 entre 1.4 y 6.6 µg/mL. Futuros estudios a nivel molecular deben 
ser realizados, los cuales podrán delucidar si el uso de IPA pudiera 
beneficiar o no a los pacientes que sufren de TE. 
Table 1
In vitro effects of antiretroviral protease inhibitors on Toxoplasma gondii RH 
strain OF-1 mice
Drugs
IC50a ± SD b 
(µg/mL)
CC50c ± SD 
(µg/mL) SId
Tachyzoites Macrophages
Atazanavir 1.4 ± 0.3* 15.9 ± 0.6 11
Fosamprenavir 3.3 ± 0.9 51.0 ± 0.9 15
Indinavir 6.6 ± 1.5 76.8 ± 1.3 12
Nelfinavir 4.0 ± 0.2 24.8 ± 0.3 6
Ritonavir 3.4 ± 0.7 26.4 ± 0.5 8
Saquinavir 2.6 ± 0.3 24.9 ± 1.1 10
Sulfadiazine 5.8 ± 0.9 6.3 ± 0.8 1
Pyrimethamine 0.3 ± 0.01 1.1 ± 0.3 4
a: IC50; Concentration of the compounds that caused 50% of mortality; b: SD; 
Standard deviation; c: CC50; Concentration of the compound that caused 50% 
of cytotoxicity on host cell; d: Selectivity index: CC50 against macrophage / IC50 
against tachyzoites of T. gondii; *: Statistical differences with respect to other 
evaluated compounds (p < 0.05)
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